Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VCYT

Veracyte, Inc.

Healthcare | Biotechnology

No licensed closing price on file for VCYT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.40

Veracyte, Inc. (NASDAQ: VCYT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 02:57 UTC.

What Veracyte, Inc. does

The company develops and commercializes diagnostic tests, including the Prosigna Breast Cancer Assay, which runs on the nCounter Analysis System platform and is available globally as an in vitro diagnostic test. The company faces challenges in adapting tests to different IVD platforms, competing in international markets with varying standards of care, and managing manufacturing through third-party contract manufacturers.

Summarized from Veracyte, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$1.40
Return on equity5.07%

Revenue, margins & earnings

FY2021: net loss $76M on revenue $220M$220MFY2021FY2022: net loss $37M on revenue $297M$297MFY2022FY2023: net loss $74M on revenue $361M$361MFY2023FY2024 Revenue: $446M — margin split not shown (non-operating gains)$446MFY2024FY2025 Revenue: $517M — margin split not shown (non-operating gains)$517MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-22
  • 2026-09-22Global Chief Commercial OffSale-4,015$160.6K
  • 2026-09-16DirectorSale-5,000$204.7K
  • 2026-09-04Chief Financial OfficerSale-2,477$106.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Veracyte, Inc. do?

The company develops and commercializes diagnostic tests, including the Prosigna Breast Cancer Assay, which runs on the nCounter Analysis System platform and is available globally as an in vitro diagnostic test.

When did VCYT last file with the SEC?

Veracyte, Inc.'s most recent SEC filing on record is a 8-K filed 2026-09-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 02:57 UTC. This page is also available as JSON at /api/data?ticker=VCYT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VCYT and 5,000+ tickers.

Create a free account — keep VCYT
For your agent
GET /api/data?ticker=VCYT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt